Sevasemten is under clinical development by Edgewise Therapeutics and currently in Phase III for Becker Muscular Dystrophy. According to GlobalData, Phase III drugs for Becker Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sevasemten LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sevasemten overview
Sevasemten (EDG-5506) is under development for the treatment of Duchenne muscular dystrophy, Becker muscular dystrophy, Limb girdle muscular dystrophy (LGMD), myocardial fibrosis and McArdle disease. It is administered through oral route. it acts by targeting myosin ATPase.
Edgewise Therapeutics overview
Edgewise Therapeutics is a pharmaceutical company that discovers, develops and commercializes of innovative products to treat severe and rare muscle disorders. The company’s product portfolio includes EDG-5506, EDG-5440 and EDG-002. Its products are used in various therapeutic areas such as duchenne, limb-girdle and becker muscular dystrophy, hypertrophic cardiomyopathy, McArdle disease (also known as Glycogen storage disease type V or GSDV) and rare neuromuscular disease. Edgewise Therapeutics collaborates with a network of experts who advise and support its development activities. The company utilizes translatable systems to identify small-molecule precision medicines which regulate key proteins in muscle tissue. Edgewise Therapeutics is headquartered in Boulder, Colorado, the US.
For a complete picture of Sevasemten’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
